Clinical trial
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic…
NCT00283829 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00283829 |
|---|---|
| Title | Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer |
| Official title | Immunotherapy With Low Dose Interleukin-2 After Cytoreductive Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer: A Phase I/II Study |
| Lead sponsor | University of Washington, Other |
| Collaborators | Sanofi Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | docetaxel, IL2 |
| Enrollment | 30 |
| Start date | Sep 1, 2002 |
| Completion | Jul 1, 2006 |
| First posted | Jan 30, 2006 |
| Last update posted | Nov 29, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: